Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E

NEUROLOGY

Semplicini C1, Vissing J1, Dahlqvist JR1, Stojkovic T1, Bello L1, Witting N1, Duno M1, Leturcq F1, Bertolin C1, D'Ambrosio P1, Eymard B1, Angelini C1, Politano L1, Laforêt P2, Pegoraro E2.

OBJECTIVE:

To determine the clinical spectrum of limb-girdle muscular dystrophy 2E (LGMD2E) and to investigate whether genetic or biochemical features can predict the phenotype of the disease.

METHODS:

All LGMD2E patients followed in participating centers were included. A specific clinical protocol was created, including quantitative evaluation of motor, respiratory, and cardiac function. Phenotype was defined as severe or mild if the age at loss of ambulation occurred before or after 18 years. Molecular analysis of SGCB gene and biochemical features of muscle biopsies were reviewed.

RESULTS:

Thirty-two patients were included (16 male, 16 female; age 7-67 years; 15 severe, 12 mild, and 5 unknown). Neurologic examination showed proximal muscle weakness in all patients, but distal involvement was also observed in patients with severe disease early in the disease course. Cardiac involvement was observed in 20 patients (63%) even before overt muscle involvement. Six patients had restrictive respiratory insufficiency requiring assisted ventilation (19%). Seventeen different mutations were identified, and 3 were recurrent. The c.377_384dup (13 alleles) was associated with the severe form, the c.-22_10dup (10) with the milder form, and the c.341C>T (9) with both. The entire sarcoglycan complex was undetectable by muscle immunohistochemistry or Western blot in 9/10 severe cases and reduced in 7/7 mild cases. The residual amount of sarcoglycan in muscle resulted a predictor of age at loss of ambulation.

CONCLUSIONS:

This study expands the spectrum of phenotype in β-sarcoglycanopathy and provides strong evidence that severity of clinical involvement may be predicted by SGCB gene mutation and sarcoglycan protein expression.

https://pubmed.ncbi.nlm.nih.gov/25862795/

  • Visite: 171

©2020 GFBONLUS.IT - GRUPPO FAMILIARI BETA-SARCOGLICANOPATIE
+39 328 0075986 Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

Via Civasca 112 23018 Talamona - SO  Italia

Made by Betsoft